Diffuse large B-cell lymphoma
Citation, DOI, disclosures and article data
At the time the article was created Francis Deng had no recorded disclosures.View Francis Deng's current disclosures
At the time the article was last revised Henry Knipe had the following disclosures:
- Integral Diagnostics, Shareholder (ongoing)
- Micro-X Ltd, Shareholder (ongoing)
These were assessed during peer review and were determined to not be relevant to the changes that were made.View Henry Knipe's current disclosures
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma.
Diffuse large B-cell lymphoma is sometimes associated with immunodeficiency, including acquired immunodeficiency syndrome.
In the 2016 WHO classification of lymphoid neoplasms, diffuse large B-cell lymphoma, not otherwise specified (NOS), is a type of mature B-cell neoplasm and includes two molecular subgroups indicating the cell of origin:
- germinal center B-cell type
- activated B-cell type
In addition, diffuse large B-cell lymphomas with certain molecular/cytogenetic features, previously called "double-hit" or "triple-hit" lymphomas, as well as those resembling Burkitt lymphoma are now classified together as either of the following entities 1:
- high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
- high-grade B-cell lymphoma, not otherwise specified
There are otherwise multiple specified types of diffuse large B-cell lymphomas:
- T-cell/histiocyte-rich large B-cell lymphoma
- primary diffuse large B-cell lymphoma of the central nervous system
- primary cutaneous diffuse large B-cell lymphoma, leg type
- Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified
- diffuse large B-cell lymphoma associated with chronic inflammation
- human herpesvirus 8-positive diffuse large B-cell lymphoma, not otherwise specified (provisional entity)
See the article on lymphoma staging.